University Of California, San Francisco

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer, Metastatic Kidney Cancer, or Aplastic Anemia

Not Applicable

Conditions: Chronic Myeloproliferative Disorders
Kidney Cancer
Leukemia
Lymphoma
Multiple Myeloma and Plasma Cell Neoplasm
Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Neoplasms

First Posted Date: 2006-02-24

Last Posted Date: 2014-01-06

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 35

Registration Number: NCT00295997

Locations: 🇺🇸
UCSF Comprehensive Cancer Center, San Francisco, California, United States
🇺🇸
Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States

Epidural Analgesia or Patient-Controlled Analgesia in Treating Patients Who Have Undergone Surgery for Gynecologic Cancer

Completed

Conditions: Fallopian Tube Cancer
Pain
Cervical Cancer
Endometrial Cancer
Ovarian Cancer
Perioperative/Postoperative Complications
Sarcoma

Interventions: Drug: hydromorphone hydrochloride
Drug: fentanyl citrate
Drug: ropivacaine hydrochloride

First Posted Date: 2006-02-24

Last Posted Date: 2014-05-20

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 240

Registration Number: NCT00295945

Locations: 🇺🇸
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States

Zoledronate in Treating Bone Marrow Micrometastases in Women With Stage I, Stage II, or Stage III Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Zoledronic Acid

First Posted Date: 2006-02-24

Last Posted Date: 2020-05-12

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 45

Registration Number: NCT00295867

Locations: 🇺🇸
University of California, San Francisco, San Francisco, California, United States

Docetaxel, Prednisone, and Vatalanib in Treating Patients With Advanced Prostate Cancer

Phase 1

Terminated

Conditions: Prostate Cancer

First Posted Date: 2006-02-17

Last Posted Date: 2012-10-11

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 6

Registration Number: NCT00293371

Locations: 🇺🇸
UCSF Comprehensive Cancer Center, San Francisco, California, United States

Celecoxib and Erlotinib in Treating Patients With Liver Cancer

Phase 1

Withdrawn

Conditions: Liver Cancer

First Posted Date: 2006-02-17

Last Posted Date: 2012-09-17

Lead Sponsor: University of California, San Francisco

Registration Number: NCT00293436

Locations: 🇺🇸
UCSF Comprehensive Cancer Center, San Francisco, California, United States

131 I-MIBG in Treating Patients With Refractory or Relapsed Neuroblastoma

Phase 2

Completed

Conditions: Neuroblastoma

First Posted Date: 2006-02-17

Last Posted Date: 2014-08-18

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 164

Registration Number: NCT00293319

Locations: 🇺🇸
UCSF Comprehensive Cancer Center, San Francisco, California, United States
🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States

Docetaxel, Carboplatin, and Bevacizumab in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer That Can Be Removed By Surgery

Phase 2

Terminated

Conditions: Lung Cancer

First Posted Date: 2006-02-17

Last Posted Date: 2011-02-09

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 1

Registration Number: NCT00293332

Locations: 🇺🇸
UCSF Comprehensive Cancer Center, San Francisco, California, United States

GP96 Heat Shock Protein-Peptide Complex Vaccine in Treating Patients With Recurrent or Progressive Glioma

Phase 1

Completed

Conditions: Brain and Central Nervous System Tumors

Interventions: Biological: HSPPC-96
Procedure: Standard Surgical Resection

First Posted Date: 2006-02-17

Last Posted Date: 2021-05-13

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 96

Registration Number: NCT00293423

Locations: 🇺🇸
Columbia University, New York, New York, United States
🇺🇸
University Hospitals Case Medical Center, Cleveland, Ohio, United States
🇺🇸
University of California, San Francisco, San Francisco, California, United States

Tamoxifen or Letrozole in Treating Women With Ductal Carcinoma in Situ

Phase 1

Completed

Conditions: Breast Cancer

Interventions: Drug: letrozole
Drug: tamoxifen citrate
Procedure: conventional surgery
Procedure: neoadjuvant therapy

First Posted Date: 2006-02-13

Last Posted Date: 2020-12-04

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 79

Registration Number: NCT00290745

Locations: 🇺🇸
University of California, San Francisco, San Francisco, California, United States

Gefitinib, Cisplatin, Irinotecan, and Radiation Therapy Before Surgery in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer That Can Be Removed By Surgery

Phase 1

Terminated

Conditions: Esophageal Cancer

First Posted Date: 2006-02-13

Last Posted Date: 2014-05-09

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 6

Registration Number: NCT00290719

Locations: 🇺🇸
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy